top of page

35+ YEARS IN MEDICAL DEVICE | PHARMACEUTICAL | BIOTECHNOLOGY | DIAGNOSTICS

Insights and News Curated for Life Science Experts by Life Science Experts....

Go back to...

Executive Spotlights

Lesson’s Learned from Building out the Commercial Organization

SK Life Science breaks through Covid barriers to bring epilepsy drug to market

Lutronic’s Focus on Change during the Pandemic

From Big Pharma to Startup: What are the Challenges?

The View from Olympus: How This MedTech Leader Approached the Pandemic

DENTALEZ COO Heather Trombley on Reinvigorating the Company

Seqirus Exec on Vaccine Differentiation

Zimmer Biomet VP on Covering the Territory

How Teleflex Grew its Market Value 4x in 6 Years

Admedus COO David St. Denis on Courage, Commitment and Conversation

Search

ZimVie Inc. Makes Strategic Move: Sells Spine Business to H.I.G. Capital for $375M

Dec 20, 2023
1 min read

Westminster, CO, December 18, 2023 (Globe Newswire) -- ZimVie Inc. (Nasdaq: ZIMV), the 2022 spin-off of the dental and spine business units of Zimmer Biomet, made waves today by finalizing a deal to sell its spine business to H.I.G. Capital, a major player in the alternative investment scene. Vafa Jamali, President and CEO notes that this allows ZimVie to focus on the global dental markets.

Read full article here.

Recent Posts

Embecta to Acquire Owen Mumford in $300M Deal to Expand Drug-Delivery Portfolio

Parsippany, NJ, March 24, 2026 (Yahoo Finance) -- Embecta has agreed to acquire Owen Mumford to strengthen its drug-delivery business. The transaction, valued at approximately $300 million, will add

ImpediMed Appoints Erik Anderson as CEO

Brisbane, CA, April 7, 2026 (ImpediMed) — ImpediMed has named Erik Anderson as its new chief executive officer. The leadership change is intended to guide the company’s strategic direction and support

Neurocrine Biosciences Details $2.9B Deal to Strengthen Pipeline

San Diego, CA, April 7, 2026 (Yahoo Finance) -- Neurocrine Biosciences has outlined a transaction valued at approximately $2.9 billion aimed at expanding its therapeutic portfolio. The deal is desig

Comments

Life Science Headlines

Embecta to Acquire Owen Mumford in $300M Deal to Expand Drug-Delivery Portfolio

ImpediMed Appoints Erik Anderson as CEO

Neurocrine Biosciences Details $2.9B Deal to Strengthen Pipeline

Hologic names Baxter's Previous Chair Jose Almieda as CEO

Gilead to Acquire Tubulis in $3.15B Deal with Up to $1.85B in Milestones

GE HealthCare Completes $2.3B Intelerad Acquisition to Expand Imaging Capabilities

Damora Therapeutics Names Jennifer Jarrett as President and CEO

Gilead Strengthens Immunology Pipeline with Up to $1.7B Ouro Medicines Deal

Field Medical Appoints Industry Veteran Mark A. Turco as CEO

Merck Expands Hematology Portfolio with $6.7B Acquisition of Terns Pharmaceuticals

bottom of page